Biosimilars and Follow-On Biologics' Trends, R&D and Revenue Forecasts 2016-2026

03 Mar, 2016, 09:00 ET from Visiongain

LONDON, March 3, 2016 /PRNewswire/ --

Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones

Biosimilars - Discover Revenue Predictions from 2016, Benefiting Your Authority
Do you want to find sales potentials of biosimilar drugs? If so, our new analysis gives you revenue forecasts to 2026 at overall world market, therapeutic class and national level.

See what is possible. For those therapies you explore sales data, R&D, opportunities and commercial prospects. Those emerging medicines hold great potential to benefit patients, healthcare providers and pharma companies.

Visiongain's updated study gives you revenue predictions for those follow-on biological drugs from 2016, helping you stay ahead. You also explore trends, technologies and expected products, benefiting your reputation for insight.

Data to help your research, plans, decisions and influence
Why struggle to find data on biosimilars, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. Avoid wasted time, struggle and missed opportunities.

Discover, in our new study, the promising future for biosimilars. Those agents include follow-on biologics (FOB) and subsequent entry biologics (SEB).

Read on, then, to explore what shapes that market, also seeing predicted revenue.

Forecasts and other analyses show you the most promising sales opportunities
That updated, expanded report shows revenue forecasting to 2026, recent results, growth rates and market shares. There you explore quantitative and qualitative analyses. That way you assess research and development, news and opportunities. Explore what the future holds, staying ahead.

Our analysis gives you 122 tables, 66 charts and two interviews with companies. With that study you assess clinical, technological and commercial trends, results and potentials. There explore issues such as these:
• Why will the biosimilars market expand fast - with predicted doubling in size many times from 2016 to 2026 - and what revenues are possible?
• When will that worldwide industry achieve overall sales in tens of billion dollars?
• What compounds give the most promise for developers, producers and sellers?
• Who are the best-placed companies in that healthcare industry from 2016?
• Where are the most promising countries for selling those biological drugs?
• How will biosimilar producers serve regulators, doctors, patients and payers?

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Many opportunities exist for those competitors of original biologics. You investigate what segments are most likely to prosper, seeing from 2016 potential sales.

See there what the future holds for follow-on protein products. The following sections explain how our study helps your work.

Predictions for that world market and submarkets - see potentials for sales growth
Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2026 for eight individual therapeutic submarkets:
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Insulin
• Erythropoietin (EPO)
• Granulocyte colony-stimulating factor (G-CSF)
• Interferons
• Growth hormones
• Fertility hormones.

That report also shows revenue forecasts to 2026 for 12 individual submarkets within those segments:
• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
• Human insulin, insulin analogues, insulin glargine and insulin lispro
• Interferon alfa and interferon beta
• Etanercept.

Our report shows sales potentials of those biopharmaceuticals, helping you find ways to develop your business. Benefit your authority on those treatments for cancer, diabetes, autoimmune diseases and other disorders, expanding your reputation for commercial knowledge.

You also find what stimulates and restrains sales of those subsequent entry biologics. Explore that industry, seeing what products can achieve the most success. So discover what revenues are possible, hearing how companies can gain.

That study also divides its overall world market forecast into geographical segments.

National markets for those therapeutic proteins - where will highest sales and growth occur?
Developments worldwide will influence that follow-on biologics market, raising demand for biosimilars in developed and developing countries. See what is possible.

Our analyses show you individual revenue forecasts to 2026 for 12 national markets:
• US
Japan
Germany, France, UK, Italy and Spain
China, India, South Korea, Russia and Brazil.

In our work you discover progress and outlooks. There you assess the biosimilar industry's future - needs, developments and demands. Our work explains, exploring issues affecting those biological drug companies, influencing their results.

Forces affecting that rising industry - what shapes its present and future?
Our new report discusses pressures, opportunities and other events affecting the biosimilars industry and market from 2016, including these influences:
• Strategies for developing biosimilars - needs, demand, challenges and opportunities
• Guidelines from regulators (FDA, EMA and others) and what they mean for those drug developers and producers - assess recent progress
• Patent challenges and data exclusivity for biopharmaceuticals
• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
• Developments in technology and operations for biosimilar drug production.

Our study also discusses other aspects of those successor biologics, including these forces:
• Economics stimulating demand for cheaper biological medicines
• Outlooks for the overall biologics market - effects of biosimilar competition
• Biobetters and other next-generation biologics as rivals to biosimilars - technological races and battles
• Collaborations for those biopharmaceutical molecules - assess deals
• Outsourcing - using contract manufacturing organisations (CMOs) - to gain expertise in pharma biotechnology, production efficiencies and cost savings.

With our report you assess that industry's strengths, weaknesses, opportunities and threats. You explore what restricts and stimulates companies, seeing the progress and sales possible.

From 2016 discover what the future holds for those drugs and their producers.

Companies and 2020 market value - what overall revenue potential?
From 2016, product launches hold great potential for investments, demand and sales. Our study predicts the world market for biosimilars and related biologics will reach $18.42 billion in 2020, multiplying in size many times from 2016 to 2026.

See how high revenues can go. With our study you assess what biosimilar technologies, products and companies hold most potential. Our analyses cover these firms and other developers, producers, marketers and sellers:
• Sandoz
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• Amgen
• Pfizer.

There you also assess these biopharma specialists, among others:
• Dr. Reddy's Laboratories
• Intas Pharmaceutical
• Mabion
• Hospira
• Celltrion.

Our work also shows you two interviews with organisations - Boehringer Ingelheim and PROBIOMED.

From 2016 many opportunities in that industry will appear. Explore, then, what the future holds, staying ahead in knowledge.

5 Ways Biosimilars and Follow-On Biologics' Trends, R&D and Revenue Forecasts 2016-2026 helps your work
In these five main ways, our new investigation helps your research, analyses, decisions, proposals and presentations:
• Revenues for biosimilars to 2026 at overall world level and for 8 main submarkets and 12 further market divisions - discover outlooks for development, production and sales
• Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - assess developed and developing countries for potential revenues
• Prospects for established competitors and rising companies - explore portfolios, results, strengths, strategies and research and development
• Analysis of what encourages and restrains biosimilar producers - investigate challenges, opportunities, regulations and competition
• Interviews with that industry - discover what other authorities think, say and do, helping you stay ahead in technological and commercial insight.

That report, by our in-house team in the UK, gives knowledge to help your work, sparing you struggles and saving time. You gain data leading companies depend on.

Data there found nowhere else, benefiting your authority on the future of biologics
Our investigation gives independent analysis. There you gain competitive intelligence found only in our survey, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in information or miss opportunity. Discover there how to help your research, analyses and decisions. Also save time and benefit your reputation for commercial insight.

So explore the future of biopharmaceuticals. In our new survey you find biosimilar results, trends, opportunities and sales predictions. Stay ahead by getting our report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1586/Biosimilars-and-Follow-On-Biologics%E2%80%99-Trends-R-D-and-Revenue-Forecasts-2016-2026

Companies Listed

Allergan
Allozyne
Alteogen
Alvogen
Amarey Novamedical
Amega Biotech
Amgen
Apotex
Argentine Ministry of Health
Astellas Pharma
AstraZeneca
Avesthagen
Baxter
Bayer
Beijing Four Rings
Beijing SL Pharmaceutical
Biocad
Bioceuticals
Biogen
BioGenomics
Biolab
Bionovis
BioPartners
Biosidus
Bioton
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Cambridge Antibody Technology
Cardiovascular and Renal Drugs Advisory Committee
Cardiovascular Drugs Advisory Committee
CCL Pharmaceuticals
CCM Duopharma
Celltrion
Centers of Medicare and Medicaid Services (CMS)
Centocor Ortho Biotech
Central Drugs Standard Control Organisation
Centre for Drug Evaluation (CDE)
China Food and Drug Administration
Chong Kun Dang
Chugai
CinnaGen.
Coherus BioSciences
Comisión Federal para la Protección contra Riesgos Sanitarios
Committee for Medicinal Products for Human Use
Compass Biotechnologies
Cristália
CT Arzneimittel
Cyplasin
Daiichi Sankyo
Department of Biotechnology (India)
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Egis Pharmaceuticals
Eisai
Eli Lilly
Elpen Pharmaceutical
Emcure Pharmaceuticals
EMS
Epirus
Eurofarma
European Generic Medicines Association (EGA)
European Medicines Agency (EMA)
Express Scripts
FibroGen
Finox Biotech
Fuji Pharma
Gan & Lee
Genetech
Genexine
Gennova
GenSci
Genzyme
Geropharm
Gilead Sciences
GlaxoSmithKline
Hangzhou Jiuyuan Gene Engineering Co.
Hanmi Pharmaceutical
Hanwha Chemical
Haselmeier
Health Canada
Helius Biotech
Hexal
Hindustan Antibiotic
Hospira
Hualida Biotech
Hypermarcas
IGES Institute
Intas Biopharmaceuticals
Intellectual Property Appellate Board (IPAB)
International Clinical Trials Registry Platform (ICTRP)
inVentiv Health
JCR Pharmaceuticals
Johnson & Johnson
Kabi
Kemwell Biopharma
Kissea
Koçak Farma
Korea Food and Drug Administration
Kwizda Pharma
Kyowa Hakko Kirin
Landsteiner Scientific
LG Life Sciences
Libbs
LKM SA
Lonza
Mabion
Marvel Life Sciences
MEDICE Arzneimittel Pütter
Merck (MSD)
Merck KGaA
Merck Serono
Mexican Supreme Court
Minapharm
Ministry for Health Labour and Welfare (MHLW)
Mitsubishi Tanabe
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mycenax Biotech
Mylan
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Nichi-Iko
Nippion Kayaku
Norwegian Ministry of Health
Novartis
Novo Nordisk
Nuron Biotech
Oncobiologics
Ortho Pharmaceutical
Orygen
Pan American Health Organization
PanGen Biotech
Pfenex
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA)
Pharmapark
Pharmstandard
PRA International
Pro Generika
PROBIOMED
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
RAND Corporation
Ratiopharm
Regeneron Pharmaceuticals
Reliance GeneMedix
Reliance Life Sciences (RLS)
Rentschler Biotechnologie
Roche
Russian Ministry of Health
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
SciGen
Scottish Medicines Consortium (SMC)
Shandong Kexing Pharma
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian
Shanghai Fosun
Shantha Biotechnics
Shinogi
Sicor Biotech
Sothema Laboratories
Spectrum Pharmaceuticals
STADA Arzneimittel
Stanford University
State Employees' Social Security and Social Services Institute (ISSSTE)
Stragen Pharma
Strides Arcolab
Syngene International
Synthon Biopharmaceuticals
Takeda
Teva
The Brazilian Ministry of Health
the Drug Regulatory Authority of Pakistan
The Ministry of Food and Drug Safety (MFDS)
The National Conference of State Legislatures (US)
The United Laboratories (TUL)
Therapeutic Goods Administration
Tianjin Hualida Biotechnology
Tonghua Dongbao
Toronto University
TSH Biopharm Corp
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
União Química
University of California, San Francisco
University of Tokyo
US Center for Disease Prevention and Control (CDC)
US Court of Appeals
US Food and Drug Administration (FDA)
US Patent and Trademark Office
USV Biologics
Virchow Biotech
Wanbang Biopharmaceuticals
Wockhardt
World Health Organization (WHO)
Xiamen Amoytop Biotech
Zenotech
Zhejian Huahai Pharmaceutical
Zuventus
Zydus Biovation
Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain